Data / Companies / CSTL
Castle Biosciences Inc.Nasdaq
CSTL-US · CIK 0001447362 · Services-Medical Laboratories
Revenue by quarter
US$ · last 8Hover a column for its exact figure
$0$50M$100M$150M
Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26
| Quarter | Revenue | Net income | EPS |
|---|---|---|---|
| Q2 FY2026 | $103.5M | -$2.1M | -0.07 |
| Q1 FY2026 | $83.7M | -$14.5M | -0.49 |
| Q4 FY2025 | $87.0M | -$2.3M | -0.08 |
| Q3 FY2025 | $83.0M | -$501.0K | -0.02 |
Newest filings
All 190| Form | Filed | |
|---|---|---|
| CERT | 17 Aug 2026 | |
| 8-A12B | 14 Aug 2026 | |
| 10-Q | 30 Jul 2026 | |
| 8-K | 30 Jul 2026 | |
| 8-K | 29 May 2026 | |
| 10-Q | 6 May 2026 | |
| 8-K | 6 May 2026 | |
| ARS | 8 Apr 2026 |
Description
- Ticker
- CSTL-US
- Exchange
- Nasdaq
- Index
- –
- Industry
- Services-Medical Laboratories
- SIC division
- Services
- CIK
- 0001447362
- Fiscal year ends
- Dec
- Filings held
- 190 since 2008
- 8-K events
- 75
- Shares short
- 2.0M, 15 Oct 2026
Financial statements
The main lines of the income statement, balance sheet and cash flow, by year and by quarter. Each period opens its filing.
5 years · US$ millions
| Fiscal period | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| Period ending | 31 Dec 2021 | 31 Dec 2022 | 31 Dec 2023 | 31 Dec 2024 | 31 Dec 2025 |
| Reported in | 10-K | 10-K | 10-K | 10-K | 10-K |
| Report filed | 28 Feb 2022 | 28 Feb 2023 | 28 Feb 2024 | 27 Feb 2025 | 26 Feb 2026 |
| Revenue | 94M | 137M | 220M | 332M | 344M |
| Cost of revenue | 16M | 32M | 45M | 60M | 71M |
| Gross profit | 78M | 105M | 175M | 272M | 273M |
| Gross margin | 83.2% | 76.6% | 79.5% | 81.9% | 79.4% |
| Research and development | 30M | 45M | 54M | 52M | 52M |
| Selling, general and administrative | 87M | 143M | 180M | 200M | 229M |
| Operating income | -40M | -73M | -68M | 9M | -43M |
| Operating margin | -42.6% | -53.2% | -30.9% | 2.6% | -12.4% |
| Income tax | -9M | -2M | 0M | 3M | -5M |
| Net income | -31M | -67M | -57M | 18M | -24M |
| Net margin | -33.3% | -49.0% | -26.1% | 5.5% | -7.0% |
| Earnings per share, diluted | -1.24 | -2.58 | -2.14 | 0.62 | -0.83 |
| Diluted shares | 25M | 26M | 27M | 29M | 29M |
Showing the last 5 years, FY2021 onwards. The full record goes back to FY2018 and comes with a data plan. See the data plans
Ratios
Worked out the same way for every company. Hover a ratio for how it is calculated.
Valuation
- Market cap
- $1.2B
- Price
- $38.51
- Price to book
- 2.50×
- Enterprise value
- $1.1B
- Market cap / sales
- 3.29×
- Dividend yield
- 0.0%
- 52-week high
- $43.04
- 52-week low
- $18.15
Profitability
- Gross margin, TTM
- 77.3%
- Operating margin
- -9.0%
- Net margin
- -5.4%
- FCF margin
- -0.1%
- ROE
- -4.1%
- ROE, 3-year average
- -5.3%
- ROCE
- -6.7%
- Interest cover
- -85.62×
Growth
- Sales growth, TTM
- 3.2%
- Sales CAGR, 3 years
- 35.9%
- Sales CAGR, 5 years
- 40.6%
- Price, 1 year
- 62.2%
- Price CAGR, 3 years
- 39.4%
- Price CAGR, 5 years
- -9.2%
Balance sheet
- Cash and equivalents
- $62.1M
- Borrowings
- $10.1M
- Net debt
- -$52.0M
- Debt to equity
- 0.02×
- Shareholders' equity
- $470.0M
- Total assets
- $561.2M
- Net debt change, 1 year
- $20.2M
Shareholders
- Shares outstanding
- 30,508,534
- Share count, last 12 months
- 5.3%
- Dividend per share, TTM
- $0.00
- Years FCF margin > 20%, of 5
- 0
Showing the last 5 years, FY2021 onwards. The full record goes back to FY2018 and comes with a data plan. See the data plans
What the company said with its results
The key points, guidance and management's own words from each of the last four results releases.
No results summary read for this company yet.
Revenue by segment
As the company reports it in the segment note of each annual report: by business, by product and by region, latest year.
By product, FY2025
- Dermatologic$216.4M 62.9%
- Non Dermatologic$127.9M 37.1%
3 years held, FY2023 to FY2025
Showing the last 5 years, FY2021 onwards. The full record goes back to FY2018 and comes with a data plan. See the data plans
Company events
Every 8-K, sorted by the event it reports, with the moment the SEC accepted it in New York time.
| 30 Jul 2026 | 8-K | ResultsInvestor update | 2.02, 7.01, 9.01 | |
| 29 May 2026 | 8-K | Shareholder vote | 5.07 | |
| 6 May 2026 | 8-K | ResultsInvestor update | 2.02, 7.01, 9.01 | |
| 26 Feb 2026 | 8-K | ResultsInvestor update | 2.02, 7.01, 9.01 | |
| 13 Jan 2026 | 8-K | ResultsInvestor update | 2.02, 7.01, 9.01 | |
| 3 Nov 2025 | 8-K | ResultsInvestor update | 2.02, 7.01, 9.01 | |
| 8 Aug 2025 | 8-K | Bylaws or fiscal year change | 5.03 | |
| 4 Aug 2025 | 8-K | ResultsInvestor update | 2.02, 7.01, 9.01 | |
| 23 May 2025 | 8-K | Shareholder voteShareholder rights changeBylaws or fiscal year change | 3.03, 5.03, 5.07, 9.01 | |
| 5 May 2025 | 8-K | ResultsInvestor update | 2.02, 7.01, 9.01 | |
| 27 Feb 2025 | 8-K | ResultsInvestor update | 2.02, 7.01, 9.01 | |
| 13 Jan 2025 | 8-K | ResultsInvestor update | 2.02, 7.01, 9.01 | |
| 4 Nov 2024 | 8-K | ResultsInvestor update | 2.02, 7.01, 9.01 | |
| 5 Aug 2024 | 8-K | ResultsInvestor update | 2.02, 7.01, 9.01 | |
| 24 May 2024 | 8-K | Shareholder vote | 5.07 | |
| 2 May 2024 | 8-K | ResultsInvestor update | 2.02, 7.01, 9.01 | |
| 27 Mar 2024 | 8-K | Leadership changeMaterial agreement | 1.01, 5.02, 9.01 | |
| 28 Feb 2024 | 8-K | ResultsInvestor update | 2.02, 7.01 | |
| 8 Jan 2024 | 8-K | ResultsInvestor update | 2.02, 7.01, 9.01 | |
| 9 Nov 2023 | 8-K | Leadership change | 5.02 | |
| 2 Nov 2023 | 8-K | ResultsInvestor update | 2.02, 7.01, 9.01 | |
| 2 Aug 2023 | 8-K | ResultsInvestor update | 2.02, 7.01, 9.01 | |
| 5 Jun 2023 | 8-K | Investor update | 7.01 | |
| 1 Jun 2023 | 8-K | Shareholder vote | 5.07 | |
| 3 May 2023 | 8-K | ResultsInvestor update | 2.02, 7.01, 9.01 | |
| 28 Feb 2023 | 8-K | ResultsInvestor update | 2.02, 7.01, 9.01 | |
| 20 Jan 2023 | 8-K | Leadership change | 5.02 | |
| 9 Jan 2023 | 8-K | ResultsInvestor update | 2.02, 7.01, 9.01 | |
| 28 Dec 2022 | 8-K | Leadership change | 5.02 | |
| 15 Dec 2022 | 8-K | Leadership change | 5.02 | |
| 2 Nov 2022 | 8-K | ResultsInvestor update | 2.02, 7.01, 9.01 | |
| 8 Aug 2022 | 8-K | ResultsInvestor update | 2.02, 7.01, 9.01 | |
| 8 Jun 2022 | 8-K | Shareholder vote | 5.07 | |
| 3 Jun 2022 | 8-K | Other events | 8.01, 9.01 | |
| 9 May 2022 | 8-K | ResultsInvestor update | 2.02, 7.01, 9.01 | |
| 2 May 2022 | 8-K | Share sale | 3.02 | |
| 7 Apr 2022 | 8-K | Material agreement | 1.01 | |
| 4 Apr 2022 | 8-K | Material agreementShare sale | 1.01, 3.02, 9.01 | |
| 17 Mar 2022 | 8-K | Material agreement | 1.01, 9.01 | |
| 28 Feb 2022 | 8-K | ResultsInvestor update | 2.02, 7.01, 9.01 | |
| 10 Jan 2022 | 8-K | ResultsInvestor update | 2.02, 7.01, 9.01 | |
| 5 Jan 2022 | 8-K | Leadership change | 5.02, 9.01 | |
| 6 Dec 2021 | 8-K | Deal completedMaterial agreement | 1.01, 2.01, 9.01 | |
| 3 Dec 2021 | 8-K | Material agreement | 1.01, 9.01 | |
| 8 Nov 2021 | 8-K | ResultsInvestor update | 2.02, 7.01, 9.01 | |
| 19 Oct 2021 | 8-K | Material agreementInvestor updateOther events | 1.01, 7.01, 8.01, 9.01 | |
| 9 Sep 2021 | 8-K | Other events | 8.01, 9.01 | |
| 9 Aug 2021 | 8-K | ResultsInvestor update | 2.02, 7.01, 9.01 | |
| 16 Jul 2021 | 8-K | Leadership change | 5.02 | |
| 14 Jun 2021 | 8-K | Shareholder vote | 5.07 |
1–50 of 75
8-K events each year
Hover a column for its exact count
05101520
'19'23'26
Every filing
The company's filings with the SEC, newest first: 190 held. Insider, fund and large-holder filings have their own tables below.
| 17 Aug 2026 | CERT | – | |
| 14 Aug 2026 | 8-A12B | – | |
| 30 Jul 2026 | 10-Q | 30 Jun 2026 | |
| 30 Jul 2026 | 8-K | 30 Jul 2026 | |
| 29 May 2026 | 8-K | 28 May 2026 | |
| 6 May 2026 | 10-Q | 31 Mar 2026 | |
| 6 May 2026 | 8-K | 6 May 2026 | |
| 8 Apr 2026 | ARS | 31 Dec 2025 | |
| 8 Apr 2026 | DEFA14A | – | |
| 8 Apr 2026 | DEF 14A | 28 May 2026 | |
| 26 Feb 2026 | S-8 | – | |
| 26 Feb 2026 | 10-K | 31 Dec 2025 | |
| 26 Feb 2026 | 8-K | 26 Feb 2026 | |
| 13 Jan 2026 | 8-K | 11 Jan 2026 | |
| 3 Nov 2025 | S-8 | – | |
| 3 Nov 2025 | 10-Q | 30 Sep 2025 | |
| 3 Nov 2025 | 8-K | 3 Nov 2025 | |
| 8 Aug 2025 | 8-K | 5 Aug 2025 | |
| 4 Aug 2025 | 10-Q | 30 Jun 2025 | |
| 4 Aug 2025 | 8-K | 4 Aug 2025 | |
| 23 May 2025 | 8-K | 22 May 2025 | |
| 5 May 2025 | 10-Q | 31 Mar 2025 | |
| 5 May 2025 | 8-K | 5 May 2025 | |
| 9 Apr 2025 | ARS | 31 Dec 2024 | |
| 9 Apr 2025 | DEFA14A | – | |
| 9 Apr 2025 | DEF 14A | 22 May 2025 | |
| 28 Mar 2025 | PRE 14A | 22 May 2025 | |
| 27 Feb 2025 | S-8 | – | |
| 27 Feb 2025 | 10-K | 31 Dec 2024 | |
| 27 Feb 2025 | 8-K | 27 Feb 2025 | |
| 13 Jan 2025 | 8-K | 12 Jan 2025 | |
| 4 Nov 2024 | 10-Q | 30 Sep 2024 | |
| 4 Nov 2024 | 8-K | 4 Nov 2024 | |
| 5 Aug 2024 | 10-Q | 30 Jun 2024 | |
| 5 Aug 2024 | 8-K | 5 Aug 2024 | |
| 24 May 2024 | 8-K | 23 May 2024 | |
| 10 May 2024 | DEFA14A | – | |
| 2 May 2024 | 10-Q | 31 Mar 2024 | |
| 2 May 2024 | 8-K | 2 May 2024 | |
| 16 Apr 2024 | EFFECT | – | |
| 12 Apr 2024 | CORRESP | – | |
| 10 Apr 2024 | ARS | 10 Apr 2024 | |
| 10 Apr 2024 | DEFA14A | – | |
| 10 Apr 2024 | DEF 14A | 10 Apr 2024 | |
| 27 Mar 2024 | 8-K | 26 Mar 2024 | |
| 7 Mar 2024 | UPLOAD | – | |
| 28 Feb 2024 | S-8 | – | |
| 28 Feb 2024 | S-3 | – | |
| 28 Feb 2024 | 10-K | 31 Dec 2023 | |
| 28 Feb 2024 | 8-K | 28 Feb 2024 |
1–50 of 150
Insider trades
Form 4 trades by officers, directors and 10% owners, last 12 months, with the shares they held after.
| 26 Oct 2026 | Juvenal Tobin WChief Commercial Officer | Sale under a trading plan | 3,288 | $33.08 | $108.8K | 45,431 | 28 Oct 2026 |
| 19 Oct 2026 | Maetzold Derek JPres. & Chief Exec. Officer | Sale under a trading plan | 8,580 | $31.91 | $273.8K | 12,484 | 21 Oct 2026 |
| 19 Oct 2026 | Maetzold Derek JPres. & Chief Exec. Officer | Sale under a trading plan | 3,198 | $31.91 | $102.0K | 4,840 | 21 Oct 2026 |
| 19 Oct 2026 | Maetzold Derek JPres. & Chief Exec. Officer | Sale under a trading plan | 2,718 | $31.91 | $86.7K | 4,114 | 21 Oct 2026 |
| 12 Oct 2026 | Juvenal Tobin WChief Commercial Officer | Sale under a trading plan | 3,288 | $33.64 | $110.6K | 48,719 | 14 Oct 2026 |
| 5 Oct 2026 | Maetzold Derek JPres. & Chief Exec. Officer | Sale under a trading plan | 8,580 | $35.57 | $305.2K | 21,064 | 7 Oct 2026 |
| 5 Oct 2026 | Maetzold Derek JPres. & Chief Exec. Officer | Sale under a trading plan | 3,198 | $35.57 | $113.7K | 8,038 | 7 Oct 2026 |
| 5 Oct 2026 | Maetzold Derek JPres. & Chief Exec. Officer | Sale under a trading plan | 2,718 | $35.57 | $96.7K | 6,832 | 7 Oct 2026 |
| 1 Oct 2026 | Oelschlager Kristen MChief Operating Officer | Sale under a trading plan | 2,807 | $35.75 | $100.3K | 14,702 | 5 Oct 2026 |
| 1 Oct 2026 | Oelschlager Kristen MChief Operating Officer | Sale under a trading plan | 1,346 | $36.38 | $49.0K | 13,356 | 5 Oct 2026 |
| 30 Sep 2026 | Juvenal Tobin WChief Commercial Officer | Sale under a trading plan | 1,034 | $34.20 | $35.4K | 52,007 | 1 Oct 2026 |
| 29 Sep 2026 | Juvenal Tobin WChief Commercial Officer | Sale under a trading plan | 5,543 | $35.50 | $196.8K | 53,041 | 1 Oct 2026 |
| 21 Sep 2026 | Maetzold Derek JPres. & Chief Exec. Officer | Sale under a trading plan | 8,580 | $35.33 | $303.2K | 21,479 | 23 Sep 2026 |
| 21 Sep 2026 | Maetzold Derek JPres. & Chief Exec. Officer | Sale under a trading plan | 3,198 | $35.33 | $113.0K | 11,236 | 23 Sep 2026 |
| 21 Sep 2026 | Maetzold Derek JPres. & Chief Exec. Officer | Sale under a trading plan | 2,718 | $35.33 | $96.0K | 9,550 | 23 Sep 2026 |
| 15 Sep 2026 | Juvenal Tobin WChief Commercial Officer | Sale under a trading plan | 3,294 | $35.14 | $115.8K | 58,584 | 16 Sep 2026 |
| 14 Sep 2026 | Juvenal Tobin WChief Commercial Officer | Sale under a trading plan | 3,306 | $32.32 | $106.9K | 61,878 | 16 Sep 2026 |
| 11 Sep 2026 | Maetzold Derek JPres. & Chief Exec. Officer | Sale under a trading plan | 8,361 | $32.00 | $267.6K | 21,702 | 15 Sep 2026 |
| 11 Sep 2026 | Maetzold Derek JPres. & Chief Exec. Officer | Sale under a trading plan | 3,124 | $32.00 | $100.0K | 14,517 | 15 Sep 2026 |
| 11 Sep 2026 | Maetzold Derek JPres. & Chief Exec. Officer | Sale under a trading plan | 2,656 | $32.00 | $85.0K | 12,339 | 15 Sep 2026 |
| 11 Sep 2026 | Maetzold Derek JPres. & Chief Exec. Officer | Sale under a trading plan | 223 | $32.78 | $7.3K | 21,479 | 15 Sep 2026 |
| 11 Sep 2026 | Maetzold Derek JPres. & Chief Exec. Officer | Sale under a trading plan | 83 | $32.78 | $2.7K | 14,434 | 15 Sep 2026 |
| 11 Sep 2026 | Maetzold Derek JPres. & Chief Exec. Officer | Sale under a trading plan | 71 | $32.78 | $2.3K | 12,268 | 15 Sep 2026 |
| 1 Sep 2026 | Oelschlager Kristen MChief Operating Officer | Sale under a trading plan | 3,952 | $33.36 | $131.8K | 13,556 | 3 Sep 2026 |
| 1 Sep 2026 | Oelschlager Kristen MChief Operating Officer | Sale under a trading plan | 200 | $34.02 | $6.8K | 13,356 | 3 Sep 2026 |
| 31 Aug 2026 | Juvenal Tobin WChief Commercial Officer | Sale under a trading plan | 1,730 | $32.81 | $56.8K | 65,184 | 2 Sep 2026 |
| 28 Aug 2026 | Maetzold Derek JPres. & Chief Exec. Officer | Sale under a trading plan | 11,472 | $33.14 | $380.2K | 22,435 | 1 Sep 2026 |
| 28 Aug 2026 | Maetzold Derek JPres. & Chief Exec. Officer | Sale under a trading plan | 2,505 | $33.14 | $83.0K | 17,850 | 1 Sep 2026 |
| 28 Aug 2026 | Maetzold Derek JPres. & Chief Exec. Officer | Sale under a trading plan | 2,129 | $33.14 | $70.6K | 15,172 | 1 Sep 2026 |
| 28 Aug 2026 | Maetzold Derek JPres. & Chief Exec. Officer | Sale under a trading plan | 257 | $33.14 | $8.5K | 11,277 | 1 Sep 2026 |
| 28 Aug 2026 | Maetzold Derek JPres. & Chief Exec. Officer | Sale under a trading plan | 956 | $33.88 | $32.4K | 21,479 | 1 Sep 2026 |
| 28 Aug 2026 | Maetzold Derek JPres. & Chief Exec. Officer | Sale under a trading plan | 209 | $33.88 | $7.1K | 17,641 | 1 Sep 2026 |
| 28 Aug 2026 | Maetzold Derek JPres. & Chief Exec. Officer | Sale under a trading plan | 177 | $33.88 | $6.0K | 14,995 | 1 Sep 2026 |
| 28 Aug 2026 | Maetzold Derek JPres. & Chief Exec. Officer | Sale under a trading plan | 21 | $33.88 | $711 | 11,256 | 1 Sep 2026 |
| 25 Aug 2026 | Juvenal Tobin WChief Commercial Officer | Sale under a trading plan | 9,050 | $35.04 | $317.1K | 66,914 | 27 Aug 2026 |
| 25 Aug 2026 | Oelschlager Kristen MChief Operating Officer | Sale outside a trading plan | 7,161 | $34.26 | $245.4K | 77,872 | 26 Aug 2026 |
| 25 Aug 2026 | Oelschlager Kristen MChief Operating Officer | Sale outside a trading plan | 5,223 | $34.64 | $180.9K | 72,649 | 26 Aug 2026 |
| 24 Aug 2026 | Oelschlager Kristen MChief Operating Officer | Sale outside a trading plan | 12,218 | $33.69 | $411.6K | 85,033 | 26 Aug 2026 |
| 17 Aug 2026 | Juvenal Tobin WChief Commercial Officer | Sale under a trading plan | 1,730 | $29.59 | $51.2K | 75,964 | 19 Aug 2026 |
| 14 Aug 2026 | Stokes FrankChief Financial Officer | Sale outside a trading plan | 24,908 | $29.77 | $741.5K | 35,177 | 18 Aug 2026 |
| 14 Aug 2026 | Maetzold Derek JPres. & Chief Exec. Officer | Sale under a trading plan | 1,100 | $30.02 | $33.0K | 21,479 | 18 Aug 2026 |
| 14 Aug 2026 | Maetzold Derek JPres. & Chief Exec. Officer | Sale under a trading plan | 2,714 | $30.02 | $81.5K | 20,355 | 18 Aug 2026 |
| 14 Aug 2026 | Maetzold Derek JPres. & Chief Exec. Officer | Sale under a trading plan | 2,306 | $30.02 | $69.2K | 17,301 | 18 Aug 2026 |
| 14 Aug 2026 | Maetzold Derek JPres. & Chief Exec. Officer | Sale under a trading plan | 278 | $30.02 | $8.3K | 11,534 | 18 Aug 2026 |
| 5 Aug 2026 | Maetzold Derek JPres. & Chief Exec. Officer | Sale under a trading plan | 2,546 | $30.68 | $78.1K | 21,479 | 6 Aug 2026 |
| 5 Aug 2026 | Maetzold Derek JPres. & Chief Exec. Officer | Sale under a trading plan | 556 | $30.68 | $17.1K | 23,069 | 6 Aug 2026 |
| 5 Aug 2026 | Maetzold Derek JPres. & Chief Exec. Officer | Sale under a trading plan | 473 | $30.68 | $14.5K | 19,607 | 6 Aug 2026 |
| 4 Aug 2026 | Maetzold Derek JPres. & Chief Exec. Officer | Sale under a trading plan | 8,421 | $30.79 | $259.3K | 33,414 | 6 Aug 2026 |
| 4 Aug 2026 | Maetzold Derek JPres. & Chief Exec. Officer | Sale under a trading plan | 3,374 | $30.79 | $103.9K | 28,407 | 6 Aug 2026 |
| 4 Aug 2026 | Maetzold Derek JPres. & Chief Exec. Officer | Sale under a trading plan | 2,866 | $30.79 | $88.2K | 24,143 | 6 Aug 2026 |
1–50 of 150
Planned insider sales
Form 144 notices, filed when the sell order goes to the broker.
| 13 Oct 2026 | Tobin JuvenalChief Commercial Officer | 13,154 | $430.9K | 12 Oct 2026 |
| 5 Oct 2026 | Derek MaetzoldOfficer | 28,992 | $1.1M | 5 Oct 2026 |
| 1 Oct 2026 | KRISTEN OELSCHLAGEROfficer | 4,153 | $147.6K | 1 Oct 2026 |
| 14 Sep 2026 | Tobin JuvenalChief Commercial Officer | 13,177 | $440.6K | 14 Sep 2026 |
| 11 Sep 2026 | Derek MaetzoldOfficer | 29,014 | $938.0K | 11 Sep 2026 |
| 25 Aug 2026 | Tobin JuvenalChief Commercial Officer | 22,500 | $787.5K | 25 Aug 2026 |
| 24 Aug 2026 | Kristen M. OelschlagerOfficer | 24,602 | $841.4K | 24 Aug 2026 |
| 14 Aug 2026 | FRANKLIN M. STOKESOfficer | 24,908 | $741.5K | 14 Aug 2026 |
| 14 Aug 2026 | Derek MaetzoldOfficer | 25,792 | $764.0K | 14 Aug 2026 |
| 31 Jul 2026 | Tobin JuvenalChief Commercial Officer | 22,500 | $630.0K | 31 Jul 2026 |
| 31 Jul 2026 | Derek MaetzoldOfficer | 67,662 | $1.9M | 31 Jul 2026 |
| 1 Jul 2026 | Derek MaetzoldOfficer | 23,844 | $589.2K | 1 Jul 2026 |
| 16 Jun 2026 | KRISTEN OELSCHLAGEROfficer | 29,911 | $618.0K | 16 Jun 2026 |
| 1 Jun 2026 | Derek MaetzoldOfficer | 14,008 | $293.7K | 1 Jun 2026 |
| 7 May 2026 | Derek MaetzoldOfficer | 14,008 | $269.5K | 7 May 2026 |
| 26 Mar 2026 | Derek MaetzoldOfficer | 18,180 | $449.0K | 26 Mar 2026 |
| 12 Mar 2026 | Tobin JuvenalChief Commercial Officer | 20,863 | $528.3K | 12 Mar 2026 |
| 11 Mar 2026 | Derek MaetzoldOfficer | 94,204 | $2.5M | 11 Mar 2026 |
| 5 Mar 2026 | FRANKLIN STOKESOfficer | 6,001 | $169.0K | 5 Mar 2026 |
| 5 Mar 2026 | GORDON B. COLEDirector | 7,403 | $210.7K | 5 Mar 2026 |
| 3 Mar 2026 | FRANKLIN STOKESOfficer | 7,000 | $195.9K | 3 Mar 2026 |
| 5 Jan 2026 | Derek MaetzoldOfficer | 12,051 | $470.0K | 5 Jan 2026 |
| 17 Dec 2025 | Kristen M. OelschlagerOfficer | 14,888 | $581.4K | 17 Dec 2025 |
| 15 Dec 2025 | Derek MaetzoldOfficer | 33,685 | $1.3M | 15 Dec 2025 |
| 11 Dec 2025 | FRANKLIN M. STOKESOfficer | 4,496 | $168.4K | 11 Dec 2025 |
| 11 Dec 2025 | TOBIN JUVENALOfficer | 13,200 | $494.7K | 11 Dec 2025 |
| 25 Nov 2025 | Derek MaetzoldOfficer | 10,712 | $427.7K | 25 Nov 2025 |
| 24 Nov 2025 | TOBIN JUVENALOfficer | 1,301 | $49.3K | 24 Nov 2025 |
| 12 Nov 2025 | FRANKLIN STOKESOfficer | 5,388 | $187.2K | 11 Nov 2025 |
| 12 Nov 2025 | TOBIN JUVENALOfficer | 5,393 | $187.4K | 11 Nov 2025 |
| 12 Nov 2025 | Kristen M. OelschlagerOfficer | 18,932 | $657.7K | 11 Nov 2025 |
| 4 Nov 2025 | Derek MaetzoldOfficer | 13,390 | $423.5K | 4 Nov 2025 |
Large holders
Schedule 13D and 13G filings by holders of more than 5% of the voting shares.
| 29 Oct 2026 | PRINCIPAL GLOBAL INVESTORS | 13G amended | 4.9% | 1.5M |
| 15 May 2026 | RTW Investments, LP | 13G amended | 9.3% | 2.8M |
| 15 May 2026 | Portolan Capital Management, LLC | 13G amended | 4.45% | 1.4M |
| 26 Mar 2026 | The Vanguard Group | 13G amended | 0% | 0 |
| 17 Feb 2026 | RTW Investments, LP | 13G | 7.2% | 2.1M |
| 21 Jan 2026 | Dimensional Fund Advisors LP | 13G amended | 3.9% | 1.1M |
Trades by members of the House
From each member's periodic transaction report: the amount is the band the report gives.
| 15 Mar 2022 | Josh GottheimerNJ05 | Sale (partial) | $1,001 - $15,000 | JT | 17 Apr 2022 |
| 23 Dec 2020 | Gilbert CisnerosCA39 | Purchase | $1,001 - $15,000 | Self | 11 Jan 2021 |
| 21 Dec 2020 | Josh GottheimerNJ05 | Purchase | $1,001 - $15,000 | JT | 7 Jan 2021 |
Short interest
Shares sold short and not yet bought back, on every FINRA settlement date.
Shares short, each settlement
| 15 Oct 2026 | 2.0M | +0.84% | 5.98 |
| 30 Sep 2026 | 2.0M | +5.28% | 4.77 |
| 15 Sep 2026 | 1.9M | -3.91% | 7.36 |
| 31 Aug 2026 | 2.0M | +12.73% | 5.05 |
| 14 Aug 2026 | 1.8M | +12.27% | 3.68 |
| 31 Jul 2026 | 1.6M | +9.86% | 3.17 |
| 15 Jul 2026 | 1.4M | -4.69% | 5.66 |
| 30 Jun 2026 | 1.5M | +0.45% | 3.18 |
| 15 Jun 2026 | 1.5M | +0.02% | 5.23 |
| 29 May 2026 | 1.5M | +4.88% | 3.78 |
1–10 of 174
Funds that hold it
Every fund's holding from its latest Form 13F, largest first, with what it added or trimmed in the quarter.
Funds holding
207
quarter to 30 Jun 2026
Added or new
95
since 31 Mar 2026
Trimmed
54
in the quarter
Largest holder
BlackRock, Inc.
$78.5M
The 60 largest of 207 funds, by value
1–50 of 60
Dividends and buybacks
Dividend per share, the cash paid and the shares bought back, each fiscal year.
Dividend per share, each fiscal year
Hover a column for its exact figure
$0$0.5$1
'21'24'25
| FY2025 | $0.00 | – | – |
| FY2024 | $0.00 | – | – |
| FY2023 | $0.00 | – | – |
| FY2022 | $0.00 | – | – |
| FY2021 | $0.00 | – | – |
Peers
Companies in the same industry, largest first, on the same measures.
| Company | Market value | Revenue, 12 months | Revenue growth | Operating margin | Net margin | ROE | P/E | EV/EBITDA |
|---|---|---|---|---|---|---|---|---|
| Castle Biosciences Inc.this company | $1.2B | $357.3M | 3.2% | -9.0% | -5.4% | -4.1% | – | – |
| Natera, Inc. | $62.6B | $2.7B | 37.8% | -10.7% | -7.1% | -10.6% | – | – |
| Labcorp Holdings Inc. | $29.8B | $14.3B | 6.4% | 10.4% | 7.0% | 11.6% | 30.4× | 16.2× |
| Quest Diagnostics Inc. | $27.8B | $11.8B | 9.1% | 14.6% | 9.5% | 14.8% | 25.2× | 14.1× |
| Guardant Health, Inc. | $24.8B | $1.2B | 42.7% | -39.7% | -38.3% | – | – | – |
| Caris Life Sciences, Inc. | $10.2B | $989.6M | – | 15.5% | 10.6% | 17.8% | 100.4× | 57.0× |
| Grail, Inc. | $7.1B | $165.3M | 23.1% | -338.4% | -236.9% | -15.4% | – | – |
| RadNet, Inc. | $5.8B | $2.3B | 18.9% | 3.1% | -0.9% | -1.9% | – | 26.4× |
| Veracyte, Inc. | $4.2B | $561.9M | 17.3% | 18.8% | 20.4% | 8.2% | 37.0× | 30.8× |
| CareDx, Inc. | $3.8B | $497.4M | 38.9% | 23.4% | 25.9% | 27.5% | 29.9× | 26.1× |
| Fortrea Holdings Inc. | $2.2B | $2.7B | -3.4% | 0.5% | -2.6% | -12.9% | – | 33.5× |
What the company does
The description for this company is being written.
Free for your personal research, with credit and a link. For API access, bulk files or commercial use, tell us what you need. The data licence